Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-blind, Randomized Controlled Study to Evaluate Immunogenicity and Safety of Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult V Olunteers

NCT03784885 is registered in ClinicalTrials.gov with Advagene Biopharma Co. Ltd. as lead sponsor.

NCT NCT03784885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03784885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-blind, Randomized Controlled Study to Evaluate Immunogenicity and Safety of Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult V Olunteers
Lead sponsor
Advagene Biopharma Co. Ltd.
Phase
Phase 2
Overall status
Completed
Start date
September 1, 2017
Completion date
October 30, 2018
Enrollment
345 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza infection